Skip to main content

Table 2 Relationship between serum lnc34a expression and clinicopathological characteristics

From: Serum lnc34a is a potential prediction biomarker for bone metastasis in hepatocellular carcinoma patients

  Serum Lnc34a Expression
Variable n Low High P
Age
  ≤ 56 78 40 38 0.577
  > 56 79 37 42  
Gender
 male 142 69 73 0.727
 female 15 8 7  
HBsAg
 negative 28 17 11 0.173
 positive 129 60 69  
HCV-Ab
 negative 152 76 76 0.387
 positive 5 1 4  
AFP
  ≤ 20 60 31 29 0.605
  > 20 97 46 51  
ALT
  ≤ 40 126 61 65 0.749
  > 40 31 16 15  
γ-GT
  ≤ 50 96 49 47 0.530
  > 50 61 28 33  
Liver cirrhosis
 no 34 18 16 0.608
 yes 123 59 64  
Child-Pugh score
 A 151 73 78 0.643
 B 6 4 2  
Tumor differentiation
 I–II 93 43 50 0.396
 III–IV 64 34 30  
Tumor size, cm
  ≤ 5 107 49 58 0.233
  > 5 50 28 22  
Tumor number
 single 98 45 53 0.313
 multiple 59 32 27  
Tumor encapsulation
 complete 72 35 37 0.920
 none 85 42 43  
Vascular invasion
 no 112 61 51 0.032
 yes 45 16 29  
BCLC stage
 0-A 99 56 43 0.014
 B-C 58 21 37  
Lung metastasis
 no 134 67 67 0.566
 yes 23 10 13  
Lymph node metastasis
 no 137 68 69 0.701
 yes 20 9 11  
Bone metastasis
 no 139 74 65 0.003
 yes 18 3 15  
  1. HBsAg hepatitis B surface antigen, HCV-Ab hepatitis C virus antibody, AFP a-fetoprotein, ALT alanine aminotransferase, γ-GT γ-glutamyl transferase, BCLC-stage Barcelona Clinic Liver Cancer-stage